Aspartate availability drives differential engagement of the malate-aspartate shuttle
The malate-aspartate shuttle is a major electron shuttle that transfers reducing equivalents from the cytosol to the mitochondria, where they can be safely deposited onto the electron transport chain. Nevertheless, many proliferating cells discard reducing equivalents in the form of lactate, raising the question of what factors limit electron shuttle use. Here, we show that aspartate availability determines engagement of the malate-aspartate shuttle. In proliferating cells, increasing aspartate availability enhances use of the malate-aspartate shuttle and increases metabolism of glucose-derived pyruvate in mitochondria, a process that requires regeneration of oxidized electron carriers in the cytosol. During differentiation, elevated flux through the malate-aspartate shuttle cells enables cells to fuel mitochondrial networks from glucose-derived carbon. Engineering aspartate demand reverses this metabolic signature of differentiated cells. Together, these results demonstrate that cell-state-specific demand for aspartate is sufficient to determine use of the malate-aspartate shuttle and drives changing mitochondrial substrate preferences during differentiation.
Authors
- Lydia W.S. Finley (ORCID: https://orcid.org/0000-0003-4023-7574)
- Benjamin T. Jackson (ORCID: https://orcid.org/0000-0003-1089-4362)
- Sangita Chakraborty (ORCID: https://orcid.org/0009-0008-7674-8150)
- Julia S. Brunner (ORCID: https://orcid.org/0000-0002-3195-147X)
- Katrina I. Paras (ORCID: https://orcid.org/0000-0001-9743-5710)
- Paige K. Arnold (ORCID: https://orcid.org/0000-0002-0851-2057)
- Maider Fagoaga-Eugui
- Anna E Bridgeman
- Julia Losner
- Abigail Xie
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- Molecular Cell
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.molcel.2026.02.004
- Citations
- 1
- Primary Topic
- Protein Structure and Dynamics
- Type
- article
- Field-Weighted Citation Impact
- 22.24
Funders
- Damon Runyon Cancer Research Foundation
- New York Stem Cell Foundation
- Memorial Sloan-Kettering Cancer Center
- Edward Mallinckrodt, Jr. Foundation
- Pershing Square Sohn Cancer Research Alliance
- Boehringer Ingelheim Fonds